Alseres Pharmaceuticals, Inc. (OTCPK:ALSE) entered into an agreement to acquire E-IACFT Injection from Navidea Biopharmaceuticals, Inc (AMEX:NAVB) for $3.4 million on July 31, 2012. Under the terms of agreement, Alseres Pharmaceuticals will pay $0.18 million in cash and the issue 0.3 million shares of Alseres Pharmaceuticals's common stock. In additional, Alseres Pharmaceuticals will pay contingent milestone payments to Alseres of up to $2.9 million and the issuance of up to an additional 1.15 million shares of the Alseres Pharmaceuticals's common stock. Kenneth Krisko of Cooley LLP acted as legal advisor for Navidea Biopharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (OTCPK:ALSE) cancelled the acquisition of E-IACFT Injection from Navidea Biopharmaceuticals, Inc (AMEX:NAVB) on April 21, 2015.